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Metal-exposureSubstantial evidence linksα-synuclein, a small highly conserved presynaptic protein with unknown function, to
both familial and sporadic Parkinson's disease (PD). α-Synuclein has been identiﬁed as the major component of
Lewy bodies and Lewy neurites, the characteristic proteinaceous deposits that are the hallmarks of PD. α-
Synuclein is a typical intrinsically disordered protein, but can adopt a number of different conformational states
depending on conditions and cofactors. These include the helical membrane-bound form, a partially-folded state
that is a key intermediate in aggregation and ﬁbrillation, various oligomeric species, and ﬁbrillar and amorphous
aggregates. Themolecular basis of PD appears to be tightly coupled to the aggregation ofα-synuclein and the fac-
tors that affect its conformation. This review examines the different aggregation states of α-synuclein, the mo-
lecular mechanism of its aggregation, and the inﬂuence of environmental and genetic factors on this process.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
α-Synuclein is a 140-amino acid protein, which is encoded by a
single gene consisting of seven exons located in chromosome 4 [1].
This protein was ﬁrst described by Maroteaux et al. in 1988 as a
neuron-speciﬁc protein localized in the presynaptic nerve terminals
and nucleus, and hence was referred to as synuclein [2]. Although
this protein is at the focus of systematic research in several laborato-
ries, its exact function is still unknown. α-Synuclein attracted signiﬁ-
cant interest in 1997 after a mutation in its gene was found to be
associated with the familial cases of early-onset Parkinson's disease
[3], and its aggregates were found to be the major components of
Lewy bodies, the hallmarks of PD [4]. Since then, several observations
have ﬁrmly established α-synuclein's involvement in the pathogene-
sis of PD. Among the strongest pieces of evidence are the following:
• Autosomal dominant early-onset PD is induced as a result of three dif-
ferent missense mutations in the α-synuclein gene, corresponding to
A30P, E46K, andA53T substitutions inα-synuclein [3, 5,6], or as a result
of the overexpression of the wild typeα-synuclein protein due to gene
triplication [7–9];
• Antibodies to α-synuclein systematically detect this protein in
Lewy bodies (LBs) and Lewy neuritis (LNs), the hallmark lesionsMedicine, College of Medicine,
MDC07, Tampa, FL 33612, USA.
sky).
rights reserved.of PD. Here, a substantial portion of total protein in these inclusions
is composed of α-synuclein [4, 10];
• The production of wild type α-synuclein in transgenic mice [11] or
expression of WT, A30P, or A53T α-synuclein in transgenic ﬂies [12]
leads to motor deﬁcits and neuronal inclusions reminiscent of PD;
• Transgenic nematodes Caenorhabditis elegans that overexpress wild-
type and mutant forms of human α-synuclein (A30P and A53T)
caused an accumulation ofα-synuclein in dopaminergic (DA) neurons
[13]. These worms failed to modulate the locomotor rate in response
to an availability of food, a function normally attributed to dopaminer-
gic neurons [13]. Furthermore, worms expressing humanα-synuclein
under control of the promoter for dopamine transporter (DAT) dis-
played age- and dose-dependent dopaminergic neurodegeneration
[14,15];
• Overexpression of human α-synuclein in the baker's yeast Saccharo-
myces cerevisiae recapitulated many important features seen in PD
[16]. Such transgenic yeast represents an important cellular tool that
is now commonly used to conﬁrm established and decipher new
clues explaining the devastating pathological role of α-synuclein in
PD [16];
• α-Synuclein-positive deposits were shown to accumulate in several
animal models where Parkinsonism was induced by exposure to
different neurotoxicants [18].
Furthermore, in recent in vitro study, where two populations of
human dopaminergic neuronal cells were cocultured: one overexpres-
singα-synuclein (donor cells) and the otherwithoutα-synuclein over-
expression (acceptor cells), α-synuclein pathology was shown to be
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aggregates. Here, α-synuclein was transmitted via endocytosis to
neighboring neurons. This eventually led to the formation of Lewy-
like inclusions in the acceptor cells, with increasing numbers of these
Lewy-like inclusions directly correlated with increasing expression
levels of α-synuclein in donor cells [17].
These and other important observations correlating α-synuclein
and PD pathogenesis have been reviewed in detail elsewhere [19–23].
These in vivo results are supported by numerous in vitro studies,
which established that the recombinant α-synuclein easily assembles
into amyloid ﬁbrils and oligomers under a variety of conditions. Ag-
gregation of α-synuclein is modulated by point mutations associated
with familial PD, various environmental factors, posttranslational
modiﬁcations, and interaction with cellular membranes and different
proteins, including chaperones and β- and γ-synucleins. Structural
differences between various aggregated forms of this protein may
be correlated with their effect in vivo.
2. Structural properties and conformational behavior of
α-synuclein
2.1. Structural properties
α-Synuclein is an abundant brain protein of 140 residues, lacking
both cysteine and tryptophan residues. This protein is present in high
concentration at presynaptic terminals and is found in both soluble and
membrane-associated fractions of the brain. α-Synuclein was estimated
to account for asmuch as 1% of the total protein in soluble cytosolic brain
fractions [24]. Several possible functions for α-synuclein have been sug-
gested, including synaptic vesicle release and trafﬁcking, fatty acid bind-
ing and physiological regulation of certain enzymes, transporters, and
neurotransmitter vesicles, as well as roles in neuronal survival [21]. The
involvement of α-synuclein in the control of the neuronal apoptotic re-
sponse and in the protection of neurons from various apoptotic stimuli
was demonstrated [25]. Knockout of all synucleins (there are three
members of the synuclein family in the vertebrata: α-, β-, and γ-
synucleins) in mice leads to age-dependent neuronal dysfunction indi-
cating that synucleins are important contributors to long-term operation
of the nervous system [26].α-Synucleinwas shown to physically interact
with at least 30 proteins, underlying its important role in cell signaling
[21, 27,28].
At the level of amino acid sequence, the structure of α-synuclein
can be divided into three regions: residues 1–60, which contain four
11-amino acid imperfect repeats (coding for amphipathic α-helices)
with a conserved motif (KTKEGV); residues 61–95, which contain
the hydrophobic and highly amyloidogenic NAC region and three ad-
ditional KTKEGV repeats; and the highly enriched in acidic residues
and prolines C-terminal region, residues 96–140. The ﬁrst two regions
comprise a membrane-binding domain, whereas the C-terminal tail is
thought to contain protein–protein and protein–small molecule in-
teraction sites.
In 1996, Weinreb et al. [29] showed that in solution, α-synuclein
has a much larger Stokes radius (34 Å) and sediments more slowly
(s20,w=1.7 S) than globular proteins of similar molecular mass, sug-
gesting that it is either elongated or unfolded. Subsequent studies
supported the idea that α-synuclein is a natively unfolded protein.
For example, Fig. 1 presents some of the data obtained in the labora-
tory of Prof. Anthony L. Fink [30]. At neutral pH, far-UV CD spectrum
of α-synuclein was characterized by a minimum in the vicinity of
196 nm and the absence of bands in the region of 210–230 nm
(Fig. 1A), while FTIR spectrum was dominated by a broad peak at
1650 cm−1 (Fig. 1B). These spectra suggested that the majority of
the molecule was unfolded [30].
The hydrodynamic properties of α-synuclein analyzed by size ex-
clusion chromatography and small-angle X-ray scattering (SAXS)
were in agreement with the results of CD and FTIR studies. However,the Stokes radius measured for α-synuclein by size-exclusion chro-
matography was notably lower than that calculated for a completely
unfolded polypeptide chain of appropriate molecular mass [30,31].
Rg values calculated for α-synuclein at neutral pH from SAXS data
using the Guinier approximation (40±1 Å, Fig. 1C) were also signiﬁ-
cantly smaller than those estimated for a random coil polypeptide of
the same length (52 Å) [30]. The analysis of SAXS data in the form of
Kratky plots provided information on the packing density and the
overall conformation of a polymer molecule [32–39]. The scattering
curve for a globular conformation is proportional to Q−4 at large
values of Q, while the scattering intensity from the expanded chain
molecule is proportional to Q−2 in the moderate Q region and to
Q−1 in the high Q region. Thus, the Kratky plot for a globular confor-
mation shows a clear peak, whereas the plot for a chain-like confor-
mation has a plateau and then rises monotonically [37]. Fig. 1D
shows that the proﬁle of the Kratky plot of α-synuclein at neutral
pH was typical for a random coil conformation. Therefore, at neutral
pH α-synuclein was shown to be essentially disordered, but more
compact than a random coil [30].
2.2. Conformational behavior of α-synuclein
The natively unfolded nature ofα-synuclein is determined by its rel-
atively lowhydrophobicity and high net charge. It is expected that alter-
ations in the protein environment leading to an increase in its
hydrophobicity and/or decrease in net charge can induce partial folding
[30]. In fact, these two structural parameters can be modulated via
changes in the environment. For example, the excess negative charge
of α-synuclein at neutral pH (pI=4.7) is expected to be neutralized
by acidiﬁcation of the protein solution, and the overall hydrophobicity
of a protein is expected to increase with increasing temperature.
In agreement with this hypothesis, α-synuclein became more or-
dered at pH 3.0 or at high temperature [30]: it gained some ordered
secondary structure (Fig. 1A and B), became a bit more compact
(Fig. 1C), and developed a rudimentary nucleus of a tightly packed
core (Fig. 1D) [30]. Furthermore, Fig. 1E shows that a protonation of
α-synuclein resulted in the transformation of this natively unfolded
protein into a partially folded conformation with a signiﬁcant amount
of ordered secondary structure, some compactness, a rudimentary
nucleus of a tightly packed core, and a high afﬁnity for ANS [30]. Com-
parable folding/compaction was observed for the protein at high tem-
peratures, and an increase in temperature was sufﬁcient to induce the
reversible formation of some ordered secondary structure in α-
synuclein (Fig. 1F) [30].
2.3. Functional misfolding of α-synuclein
The partial compactness of α-synuclein represents an illustration of
a functional misfolding concept, according to which intrinsically disor-
dered proteins (IDPs) contain the preformed binding elements which
might be involved in a set of non-native intramolecular interactions.
In this way, a polypeptide chain of an IDPmisfolds to sequester the pre-
formed elements inside the non-interactive or less-interactive cage,
therefore preventing these elements from the unnecessary and
unwanted interactions with non-native binding partners [40]. Data
below provide support for this conclusion.
Recently, Eisenberg and coworkers have been able to crystallize sever-
al peptides derived from the ﬁrst 72 residues of α-synuclein fused to
maltose binding protein for increased solubility [41]. Their data showed
that residues 1–13 and 20–34 of α-synuclein formed α-helices under
the crystallization conditions, whereas the rest of the sequence remained
substantially unfolded [41]. In NMR studies, the Cα secondary chemical
shifts analysis of the unbound α-synuclein revealed that this protein is
largely unfolded and devoid of tertiary structure [42]. However, NMR
[43–47], EPR [48], molecular dynamics [44], and electron transfer studies
[49] demonstrated a relative compactness of α-synuclein compared to
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presence of transient long-range contacts within the protein structure.
These data indicated that the compactness of α-synuclein structure was
due primarily to clustering of hydrophobic residues. Similar to other na-
tively unfoldedproteins,α-synuclein can bedescribed as a highly dynam-
ic ensemble of preferred conformations [50,51]. Structural constraints for
this conformational ensemble have been obtained by NMR and EPR spec-
troscopy. For example, an overall preference for helical structure was
found in the N-terminal 100 residues, and a speciﬁc region, from residues
6 to 37, was proposed to have nascent or transient α-helical structure
[42].
Based on the measurements of 15N relaxation rates in the un-
bound form of α-synuclein, it has been concluded that regions around
residues 20 and 120 possessed decreased mobility [52]. The existence
of long-range contacts between the C-terminal tail and the central re-
gion of the protein was established using the paramagnetic relaxation
enhancement (PRE) [53]. The presence of long-range contacts sug-
gested that the native state of α-synuclein was composed of a more
compact ensemble of species than would be expected for a random
coil state [53]. When the putative structural ensemble of the unbound
α-synuclein molecules was generated by MD simulations using the
CHARMM force-ﬁeld and 20 protein replicas, it became evident that
the protein ensemble samples had non-random conformations in-
volving, in particular, contacts between residues ~120–140 of the C-
terminus and residues ~30–100 in the central region of the protein
sequence [53]. Analogous PRE experiments, in which the nitroxide
radical MTSL was attached to the introduced cysteines at positions
18, 90, and 140, suggested that the numerous long-range interactions
were present, leading to the formation of a hydrophobic cluster that
comprised the C-terminal part of the highly hydrophobic NAC region
(residues 85–95) and the C terminus (residues 110–130), probably
mediated by M116, V118, Y125, and M127. Within the C-terminal do-
main, residues 120–130 were shown to contact residues 105–115,
and the region in the vicinity of residue 120 also interacted with the
N terminus in the vicinity of residue 20 [46]. The existence of these
long-range interactions was suggested to play a role in inhibition of
the spontaneous α-synuclein oligomerization and aggregation [46,
53]. The autoinhibitory conformations ﬂuctuate in the range of nano-
seconds to micro-seconds, corresponding to the time scale of second-
ary structure formation during folding [46]. This nascent highly
dynamic tertiary structure was shown to be released by α-synuclein
interaction with polyamine or by temperature increase; i.e., under
conditions that induce α-synuclein aggregation in vitro [46].
The C-terminus of α-synuclein (residues 120–140) is very acidic
and negatively charged (−8 net charge: 8 negative charges, no posi-
tive charges), whereas the central region (residues 30–100) is slightly
positively charged (+3 net charge: 9 positive and 6 negative
charges). The electrostatic attraction between these two regions
might, at least in part, be responsible for the long-range interactions
in α-synuclein. This hypothesis is supported by accelerated ﬁbrilla-
tion of α-synuclein induced by polyamine that binds and neutralizes
the negative charges of C-terminus [47, 54]. Furthermore, a hydro-
phobic cluster was found at the C-terminus of α-synuclein. This clus-
ter was shown to be stabilized by the long-range interactions as well
[46,47]. These long-range hydrophobic and electrostatic interactions
in native α-synuclein were affected by the methionine oxidation [55].
Fig. 2 illustrates the structural diversity of α-synuclein and repre-
sents 3D-structure of this protein bound to vesicles [48, 56]; 3D-
structures of C- and N-terminal fragments of this proteins bound to
a single domain camelid antibody [57] or to a coiled-coil domain of
synphilin-1 [58]; and some representatives of the ensemble of struc-
tures found for this protein in the unbound form [46]. Fig. 2 clearly
shows that α-synuclein and its N- and C-terminal fragments adopt
very different structures in various complexes and in the unbound
form. Here, partial compaction of the unbound α-synuclein driven
by the sequestering of the protein's N- and C-termini via theirinteractions with each other and with the central NAC region repre-
sents an illustration of the functional misfolding mentioned above
[40].
All the data summarized above clearly show that α-synuclein be-
longs to the family of intrinsically disordered proteins (IDPs), and
more speciﬁcally to the subfamily of the most disordered members
of this protein family, known as natively unfolded proteins, which
are characterized by a unique combination of low overall hydropho-
bicity, low sequence complexity and high net charge [49]. Generally
speaking, IDPs exist as dynamic and highly ﬂexible structural ensem-
bles, either at the secondary or at the tertiary structure level. In con-
trast to ordered proteins whose 3-D structure is relatively stable and
Ramachandran angles vary only slightly around their equilibrium po-
sitions with occasional cooperative conformational switches, intrinsi-
cally disordered proteins or regions exist as dynamic ensembles in
which the atom positions and backbone Ramachandran angles vary
signiﬁcantly over time with no speciﬁc equilibrium values, and typi-
cally undergo non-cooperative conformational changes. IDPs include
both extended (random coil-like) regions with perhaps some second-
ary structure, and collapsed (partially folded or molten globule-like)
domains with poorly packed side chains [59].
3. Pathways and molecular determinants of α-synuclein
misfolding and aggregation
3.1. Structure and polymorphism of α-synuclein ﬁbrils
Two structural classes of amyloid ﬁbrils have been proposed:
those derived from folded proteins, and those derived from intrinsi-
cally disordered proteins. Amyloid ﬁbrils are formed from folded pro-
teins by either the refolding mechanism or by a gain-of-interaction
model [60]. In the refolding model, proteins such as insulin convert
from native structures to ﬁbrils by initially unfolding, and then refold-
ing into a secondary structure that is rich in β-sheets. Fibrils formed
in this way are stable due to backbone hydrogen bonding, rather
than side chain-side chain interactions. Alternatively, native proteins
such as transthyretin (TTR), yeast prion Sup35, superoxide dismutase
(SOD), and β2-microglobulin undergo a limited conformational
change to expose a short segment of a previously inaccessible region.
This region can then interact with the surfaces of other molecules to
form ﬁbrils without causing a major perturbation in the protein's na-
tive structure. Fibrils are formed through 1) direct stacking of ex-
posed regions (TTR and SOD) [61,62], 2) swapping of two β-sheet
containing domains from two monomers to form a cross-β spine
(Sup35 and β2-microglobulin) [63,64], or 3) strand-swapping be-
tween two adjacent monomers [65]. All of these native-like proteins
are rich in β-structure, and as a result form ﬁbrils with minimal alter-
ations to their native structures.
α-Synuclein belongs to a class of intrinsically disordered amyloid
proteins that formﬁbrils by converting either all or part of the previous-
ly unstructured polypeptide into well-deﬁned, β-sheet rich secondary
structures. Other examples of these amyloids include islet amyloid
polypeptide (IAPP), tau, and Aβ. The atomic structure of cross-β spines
inα-synuclein ﬁbrilswasﬁrst determined byX-ray crystallography and
by X-ray diffraction of synthetic human synuclein ﬁlaments and ﬁla-
ments extracted from DLB and MSA brains [66]. These studies were
later conﬁrmed by X-ray diffraction ofmany short amyloid peptides, in-
cluding a small segment from α-synuclein [64, 67]. Together, these
studies revealed thatα-synuclein ﬁbrils are composed of several proto-
ﬁlaments containing a cross-β structure in which β-strands are ar-
ranged in parallel, and the β-sheets are in-register with highly
ordered amino acid side chain patterns exposed on the surface of the
β-sheets. Furthermore, the side-chains protruding from the two β-
sheets of the cross-β spine interdigitate in a self-complementary man-
ner to give rise to highly ordered structures known as steric zippers.




Fig. 1. Structural properties and conformational behavior of human α-synuclein. A. Far-UV CD spectra measured under different conditions. B. FTIR spectra measured for natively
unfolded, partially folded and ﬁbrillar forms of α-synuclein. Guinier (C) and Kratky plot (D) representation of the results of SAXS analysis of human α-synuclein at different exper-
imental conditions: 1 — pH 7.5; E. pH-Induced partial folding of α-synuclein. F. Temperature-induced folding of α-synuclein. Modiﬁed from [30].
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face between β-sheets is not unique to ﬁbrils formed by α-synuclein,
but is a highly conserved commonmotif that is fundamental to parallel
β-sheet-rich amyloid ﬁbrils formed by many amyloid proteins, such as
tau, the PrP, insulin, IAPP, lysozyme, and β2-microglobulin [67].
Recent studies using high resolution cryo-electron microscopy,
atomic force microscopy, and solid state and quenched hydrogen/
deuterium exchange NMR spectroscopy have revealed that α-
synuclein ﬁbrils exhibit a distinct structural polymorphism. These
morphological differences are likely due to variations in the folding
of the β-sheets, differences in the molecular packing between sheet
interfaces, or interactions of side chains with the environment. In
fact, subtle changes in buffer conditions such as the pH, temperature,
ion concentration, and external variables such as agitation or toxins
can drastically inﬂuence the folding and aggregation processes of α-
synuclein. Cryo-electron microscopy and solid state NMR revealed
that the morphology of both recombinant α-synuclein (30–110)ﬁbrils and ﬁlaments extracted from PD patient brains can be classiﬁed
as either straight or twisted ribbons [68,69]. At the molecular level,
both types of ﬁbrils share a common ﬁve-layered parallel, in-
register β-sheets core that consists of a ﬁve-layered β-sandwich [68,
70]. However, these two types of ﬁbrils differ signiﬁcantly in the ar-
rangements of protoﬁlaments. Recent evidence from solid state and
quenched hydrogen/deuterium exchange NMR further proposes
that the straight ﬁbrils have protoﬁlaments (β4 and β5) aligned uni-
directionally with each other to form a ﬁbril, whereas in the twisted
ﬁbril type, two protoﬁlaments (residues 20–30) twist around each
other, giving rise to a sub-protoﬁlament that can twist again with an-
other sub-protoﬁlament to form a ﬁbril. These results show how the
differences in the ﬁbril architecture at the molecular level are trans-
lated into differences in their morphology.
The observation that various amyloid proteins assemble into high-
ly ordered β-sheet-rich ﬁbrillar aggregates independent of their pri-
mary amino acid sequence suggested that amyloid proteins misfold
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form intermediate, transient oligomeric structures and then assemble
into more structurally ordered ﬁbrillar aggregates. In accordance with
this theory, puriﬁed α-synuclein assembles into β-sheet-rich ﬁbrillar
aggregates under speciﬁc conditions in vitro [71,72]. The formation of
α-synuclein ﬁbrils occurs in a nucleation-dependent manner, where
the rate-limiting step is the spontaneous formation of small metasta-
ble oligomeric intermediates, also known as ﬁbril nuclei [73–75].
Such intermediates result from partial folding and aggregation of un-
structured α-synuclein, and exist in rapid equilibrium with its mono-
meric form. Once ﬁbril nuclei have formed, ﬁbrils are then grown by a
“dock and lock” mechanism, in which monomers initially bind to, or
“dock onto”, the exposed regions of a ﬁbril in a reversible manner.
The docking step is then followed by an irreversible re-organization
of the ﬁbril surface, which generates the most optimal surface area
for further ﬁbril growth [76,77]. A similar nucleation-dependent prin-
ciple applies to α-synuclein oligomerization, such that the formation
of oligomers is also a highly ordered process that involves an intrinsic
rate-limiting lag phase.
α-Synuclein aggregation can occur through multiple pathways that
can give rise to structurally distinct oligomeric and ﬁbrillar species. As de-
scribed in the preceding section, the process of amyloidogenic protein
misfolding is highly inﬂuenced bymany environmental and intrinsic fac-
tors, such as mutations, the pH of the environment, the presence of chap-
erones, the aggregationpropensity of theprotein in question, and so forth.
Nevertheless, a wide range of amyloidogenic proteins have been shown
to assemble into common oligomeric and ﬁbrillar conformations. This
fact suggests that amyloid misfolding is largely mediated by peptide-
backbone interactions, and not by interactions of the side groups [78].
3.2. Structures of α-synuclein oligomers
Oligomers ofα-synuclein, similar to those of other amyloidogenic pro-
teins, are highly structurally diverse. Some of themareβ-sheet rich, while
others are primarily disordered. Recent studies identiﬁed several distinct
populations ofα-synuclein oligomers and obtained their structural infor-
mation. For example, Giehm and coworkers identiﬁed wreath-like oligo-
merswith a diameter of approximately 18 nm [79]. These oligomerswere
able to disrupt the membranes and easily assembled into ﬁbrils. Hong et
al. identiﬁed the oligomers that formed in parallel with ﬁbril formation
[80]. Their morphology depended on salt concentration in solution.
These oligomers did not incorporate into ﬁbrils but disrupted the lipid
membranes. Apetri et al. found that oligomers formed at the early stages
of α-synuclein aggregation are primarily α-helical [81]. Glabe and co-
workers developed conformation-speciﬁc antibodies to distinguish be-
tween different structural classes of amyloid oligomers [82,83]. They
identiﬁed at least three structural classes of amyloid oligomers (ﬁbrillar,
preﬁbrillar and annular) and found that α-synuclein formed oligomers
from all three classes, depending on the experimental conditions
[83–85]. The oligomeric structures formedbyα-synuclein in the presence
of metal ions, small molecules, chaperones, and chemical modiﬁcations
will be discussed in detail below.
These examples show the conformational diversity of α-synuclein
oligomers. This structural diversity is translated to variability in cyto-
toxicity and biological activity.
3.3. Propagation of α-synuclein aggregates in animal models of PD and in
vitro
The seeding and propagating properties of α-synuclein aggre-
gates have been elegantly demonstrated by recent cell culture stud-
ies. In human embryonic kidney (QBI-293) cells that are
overexpressing α-synuclein, exogenous α-synuclein ﬁbrils promot-
ed and induced endogenous α-synuclein to form LB-like intracellu-
lar inclusions. These intracellular aggregates exhibited typical
pathological characteristics earlier described for LBs and LNs fromPD brains, such as hyperphosphorylation, ubiquitination, insolubili-
ty in detergent, recognition by conformation-speciﬁc antibodies,
and staining by thioﬂavin S dye [86]. Intracellular propagation of
α-synuclein ﬁbrils was dependent on the presence of a ﬁbril-
forming core, further conﬁrming in vitro experiments that demon-
strated nucleation-dependent ﬁbrillation of α-synuclein [71, 87].
Seeding of endogenous α-synuclein is not speciﬁc to the ﬁbrils,
but was also previously described for α-synuclein oligomers, in
which three distinct types of oligomers promoted intracellular olig-
omer seeding of endogenous α-synuclein in cultured human neuro-
blastoma (SH-SY5Y) cells [88]. Lastly, the propagation and
spreading of misfolded synuclein is reported in cases where
human PD patients that received embryonic nigral transplants. In
these cases, the embryonic dopaminergic neurons grafted into PD
patients developed α-synuclein inclusions and have reduced the
dopamine transporter over a period of 14 years [89]. Taken togeth-
er, these in vitro and in vivo studies synergistically suggest that mis-
folded α-synuclein aggregates propagate and spread in a disease
through an amyloid-speciﬁc, nucleation-dependent seeding mecha-
nism that is similar to the self-propagating mechanism of infectious
prion proteins [90,91].
3.4. α-Synuclein aggregation and cell death
There are two important questions regardingα-synuclein aggregation
in PD:which species present during the aggregation ofα-synuclein could
be responsible for the neuronal death, and can the neurotoxicity even be
ascribed to a single aggregate type? Toxicity may be exerted by speciﬁc
populations of α-synuclein aggregates directly and/or mediated via vari-
ous routes through proteins involved in different cellular processes
[92–94].
The mechanisms proposed to describe the neurotoxicity of α-
synuclein and its aggregates can be grouped into three major classes —
mechanical disruption of cellular compartments/processes, toxic gain
of function, and toxic loss of function. Oneof themost commonly accept-
ed examples of the former is permeation of cellular membranes by am-
yloid aggregates. α-Synuclein oligomers can bind to lipid membranes
and disrupt membrane bilayers [94–96]. Certain oligomeric forms of
α-synuclein were shown to penetrate membranes, forming pore-like
channels [79, 97]. Membrane permeation by amyloid oligomers without
pore formation has also been proposed [98]. It is believed that this is one
of the main mechanisms of toxicity for protein aggregates.
Alternatively, impairment of α-synuclein degradation via protea-
some inhibition by the aggregated species and copper-dependent
generation of ROS have been proposed as possible mechanisms for
neurotoxicity of α-synuclein aggregates [93, 99]. It is possible, and
in fact quite likely, that multiple toxic aggregated species of α-
synuclein that utilize different mechanisms of toxicity are present in
vivo. In addition, several studies stress that α-synuclein-related neu-
rotoxicity might arise from a loss of function (summarized in [99]).
All the factors mentioned above are not necessarily mutually exclu-
sive, but instead may be synergistic.
The capability of the PD-related A30P mutation to dramatically accel-
erate the initial oligomerization ofα-synuclein and to signiﬁcantly retard
the formation of mature ﬁbrils [100–103] is only one piece of evidence
which suggests that oligomeric intermediates of α-synuclein, rather
than mature ﬁbrils, may in fact be the disease-associated species of the
protein [104], and that oligomers, not ﬁbrils, are cytotoxic [105,106]. Sev-
eral additional facts in support of the idea of oligomer toxicity are listed
below [107,108]:
• In cell models, toxicity is usually seen without heavily aggregated
α-synuclein, leading to the suggestion that some soluble species
mediate toxicity [109];
• Detectable aggregation of α-synuclein and deposition of this pro-
tein into insoluble fractions occur later than cell death in vitro [110];
Fig. 2. Structural characterization of α-synuclein and its fragments in bound and unbound states. A and B. 3D-structures of α-synuclein bound to vesicles (PDB IDs: 1XQ8 and 2KKW) [48, 56]. C. 3-D structure of the C-terminal fragment
bound to a single domain of camelid antibody (PDB ID: 2X6M) [57]. D. 3-D structure of the N-terminal fragment of α-synuclein bound to the coiled-coil domain of synphilin-1 (based on PDB ID: 2KES) [58]. E. Representative conformations
of the unbound α-synuclein calculated from PRE data. Shown are the stereo-pairs of seven most populated clusters containing 80, 75, 46, 39, 25, 24, and 20 structures representing 50% of all calculated conformations. Each of these seven
clusters represents the 10 lowest-energy structures within an atomic density map calculated from all conformations contained in each cluster. RDCs were mapped onto the structures with the use of a continuous color scale, together with
the representatives of the ensemble of native structures found for this protein in the unbound form. In each cluster, positions of some of the key residues (M1, A30, T72, V82, K102, M127, and A140) are indicated. Plot E is modiﬁed from [46].















267L. Breydo et al. / Biochimica et Biophysica Acta 1822 (2012) 261–285• Transgenic mice expressing A53T and WT exhibited neurodegen-
eration outside the substantia nigra without ﬁbrillar inclusions
[111];
• Lentiviral-based expression of human α-synuclein in rat substantia
nigra resulted in selective dopaminergic toxicity with nonﬁbrillar
inclusions [112];
• The α-synuclein-containing inclusions in some animal models do
not contain ﬁbrils, and the ﬁbril-containing inclusions found in
the ﬂy PD model can occur in the absence of neurodegeneration
[113,114];
• Loss of dopaminergic neurons was the highest in transgenic mice
expressing oligomer-forming E35K and E57K α-synuclein mutants
and the lowest in those expressing a ﬁbril-formingA53Tmutant [115].
This data allows us to make a conclusion that, similar to other neuro-
degenerative diseases, there is a lack of correlation between α-synuclein
ﬁbril accumulation and neurotoxicity, making it likely that oligomers are
the neurotoxic species.
4. Roles of posttranslational modiﬁcations
The effect of post-translationalmodiﬁcations (PTMs) on protein sec-
ondary structure and susceptibility to conformational changes can be
dramatic [116]. Both the spectrum and the range of the PTM-induced
changes are very broad, as they are produced by such diverse processes
as proteolysis, phosphorylation, lipidation, S-nitrosylation, nitration,
oxidation, glycosylation, methylation, adenosine diphosphate (ADP)-
ribosylation, acylation (acetylation, isoprenylation, myristoylation),
ubiquitination, sumoylation, sulfation, farnesylation, and many others
[117]. Protein aggregation is a highly cooperative process, and even a
small subpopulation of modiﬁed α-synuclein could have a substantial
impact on kinetics and product distribution. Here we will survey the
most common types of spontaneous modiﬁcations in α-synuclein and
their known effects on its conversion into disease-related forms.
The peculiarities of α-synuclein PTMs and their roles in modulation
functions and aggregation of this protein have been covered in an excel-
lent review [118]. It has been pointed out that out of >300 known PTMs
[116,117], only a fewhave been described forα-synuclein [118]. This in-
cludes phosphorylation, nitration, dityrosine crosslinking, methionine
oxidation, glycosylation, ubiquitination, sumoylation, AGE adduct for-
mation, crosslinking by transglutaminase, truncation, and N-terminal
acetylation. The known sites of PTMs in α-synuclein are shown in
Fig. 3 and discussed below.
4.1. Phosphorylation
In human α-synuclein in vivo, serine 129 was established as a major
phosphorylation site,with a secondphosphorylation site located at serine
87 (Fig. 3A, red circles). Both of these sites are highly conserved. Casein
kinases CK1 andCK2 [119], andG-protein coupled protein kinases are be-
lieved to be responsible for phosphorylation at these sites. It is interesting
to note that the degree of α-synuclein phosphorylation (mostly at Ser-
129) is signiﬁcantly elevated in α-synuclein deposits in DLB, MSA, and
PD brains [120–122]. It has been estimated that 90% of α-synuclein in
LBs is phosphorylated at Ser-129 [120].
The effect of phosphorylation at Ser-129 on aggregation of α-
synuclein has been studied by expressing the S129A α-synuclein mu-
tant incapable of phosphorylation or the S129D mutant as a mimic of
phosphoserine [123–125]. The authors found that α-synuclein phos-
phorylation at this position enhanced the formation of aggregates,
whereas treatment with the casein kinase 2 inhibitor or S129A muta-
tion had the opposite effect [124]. Reduction of Ser-129 phosphoryla-
tion by promoting the phosphatase activity in transgenic mice leads
to decrease in α-synuclein aggregation and improved motor perfor-
mance [126]. This data shows that Ser-129 phosphorylation promotes
aggregation of α-synuclein. Phosphorylation at Ser-87, on the otherhand, expands the structure of α-synuclein, increases its conforma-
tional ﬂexibility, and blocks its aggregation in vitro[127]. Phosphory-
lation of Tyr125 was also found in the human brain and was shown
to attenuate the conversion of α-synuclein to toxic oligomers
[128,129]. The effect of phosphorylation of the structure and aggrega-
tion of α-synuclein has been found to be highly dependent on the po-
sition of the modiﬁcation.
4.2. Oxidative modiﬁcations
4.2.1. Tyrosine oxidation
As α-synuclein does not have cysteines and tryptophanes, the pri-
mary targets for oxidative modiﬁcations are its methionine and tyro-
sine residues. The α-synuclein primary sequence contains four
tyrosine residues: Tyr-39, Tyr-125, Tyr-133, and Tyr-136 (Fig. 3,
blue circles). These tyrosine residues are conserved in all α-
synuclein orthologs and in β-synuclein paralogs, suggesting that
these residues might play important functional roles [21]. Common
chemical modiﬁcations of tyrosine residues are nitration and oxida-
tive dimerization (Fig. 4A and B). Tyrosine residue can be converted
to 3-nitrotyrosine via spontaneous or peroxidase-catalyzed reaction
with peroxynitrite [130]. This modiﬁcation decreases the pKa value
of the tyrosine hydroxyl by approximately 3 units to 7.2. It has been
shown that all four tyrosines in α-synuclein can be subjects to nitra-
tion [131–135] both in vitro and in LBs from the brains of PD patients.
However, in a cellular model of PD, only a signiﬁcant increase in nitra-
tion of Tyr-39 was detected while nitration levels of other tyrosine
residues were unchanged [136]. The difference could be due to a higher
accessibility of Tyr-39 to a nitrating agent. Nitration of either Tyr-39 or
C-terminal tyrosines in vitro leads to decreased binding of α-synuclein
to lipid membranes. Nitration of C-terminal tyrosines leads to further
unfolding of α-synuclein [135, 137]. Nitrated α-synuclein was unable
to form ﬁbrils by itself (probably due to oligomer formation) but its
presence accelerated ﬁbril formation from unmodiﬁed protein [135].
Nitrated α-synuclein was highly toxic to dopaminergic neurons and
causedmotor dysfunction in rats, presumably due to the same oligomer
formation [138]. Treatment of α-synuclein with oxidizing or nitrating
agents can also result in oxidative crosslinking of tyrosines [139] and
other residues [132]. Tyrosine crosslinking has been shown to promote
oligomerization of the protein and inhibit its transition to ﬁbrils [132,
139,140].
4.2.2. Methionine oxidation
Methionine residues are also susceptible to oxidation to sulfoxide
and ultimately sulfone (Fig. 4C). All four methionines in α-synuclein
(Met-1, Met-5, Met-116, and Met-127) located outside the repeat-
containing region (see Fig. 3, yellow circles) are highly susceptible
to oxidation to methionine sulfoxide in vitro[141–144]. Oxidized me-
thionines often disrupt protein structure, since methionine sulfoxide
is signiﬁcantly more polar and rigid than methionine [145].
Methionine-oxidized α-synuclein was found to be more highly un-
folded than the non-oxidized protein [141, 143,144], less prone to
form oligomers and ﬁbrils, and even able to inhibit the ﬁbrillation of
non-modiﬁed α-synuclein [143]. The inhibition α-synuclein ﬁbrilla-
tion by methionine oxidation was shown to be proportional to the
number of oxidized methionines. It has been proposed that methio-
nine oxidation disrupts end-to-end association of α-synuclein re-
quired for ﬁbril formation and thus directs its aggregation toward
less structured, non-toxic oligomers [55, 146]. Methionine sulfoxides
have been shown to bind metal ions with some multivalent ions able
to act as a bridge between two or more of them. Such inter- or intra-
molecular coordination of multiple methionine sulfoxides could sig-
niﬁcantly alter the protein structure. Indeed, ﬁbrillation of oxidized
α-synuclein was promoted by Ti3+, Zn2+, Al3+, and Pb2+ ions but
not by Hg2+, Cu2+, and Ca2+ [144].
AB
C
Fig. 3. Schematic representation of α-synuclein structure with the emphasis on: A, pe-
culiarities of primary structure; B, the putative interaction domains; C, intrinsic disor-
der predictions. Plot A shows three AS isoforms of α-synuclein (1a, 1b, and 1c); three
formal structural domain (2); seven imperfect repeats (3); predicted (4a) and experi-
mentally determined α-helices (4b); sites of posttranslational modiﬁcations (methio-
nines, yellow circles; tyrosines, blue circles; phosphorylation sites (red circles);
ubiquitination, green boxes; sumoylation, brown box; tTG crosslinking sites, red
ovals) and PD-related mutations (three red stars) (5). Plot B represents interaction do-
mains responsible for binding of several ligands and proteins. The numbers on the bars
correspond to the residues in α-synuclein sequence. Modiﬁed from [21]. Plot C repre-
sents results of the intrinsic disorder prediction using IUPred (pink dashed line); RONN
(blue dashed line); PONDR VSL2 (red dashed line) and PONDR VL3 (cyan dashed line).
The results averaged over these for predictions are shown as solid dark yellow line.
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Since PD pathology is associated with dopaminergic neurons, the
interaction between α-synuclein and dopamine has been extensively
investigated [147]. Dopamine is known to bind to α-synuclein non-
covalently, inhibiting its ﬁbrillation and stabilizing the oligomers
[148]. However, dopamine is highly susceptible to oxidation, and its
oxidation products form adducts with α-synuclein [146, 149]. These
adducts drive aggregation of α-synuclein into primarily unstructured,
SDS-resistant oligomers [146, 149,150].
Overall, oxidative modiﬁcation can signiﬁcantly alter the aggrega-
tion pathway of α-synuclein, usually toward oligomer formation. The
structure and toxicity of these oligomers depend on the nature of
modiﬁcation and other experimental variables.
4.3. Lysine modiﬁcation
4.3.1. Ubiquitination
Ubiquitin is a small protein that can be enzymatically attached to ly-
sine residues of various cellular proteins. Ubiquitination is used to target
proteins for proteolytic degradation. Although α-synuclein contains 15
lysine residues, only Lys-6, Lys-10, and Lys-12 were shown to be ubiqui-
tinated in vivo (see Fig. 3, green boxes) [151]. Since ubiquitination is not
required for the degradation of theα-synucleinmonomer, it appears that
α-synuclein ubiquitination occurs after its aggregation [152]. Not sur-
prisingly, ubiquitinated α-synuclein is present in both LBs during PD
[153] and in cytoplasmic inclusions during MSA [154]. The effect of
monoubiquitination of α-synuclein on its aggregation depends on the
site of modiﬁcation. For example, α-synuclein monoubiquitinated at
Lys-6 aggregated much slower than the unmodiﬁed protein [155]. How-
ever,monoubiquitination ofα-synuclein by SIAH ligase atmultiple lysine
residues promoted the formation of cytotoxic aggregates both in vitro
and in vivo[156]. Overexpression of Parkin (a ubiquitin ligase) or ubiqui-
tin in Drosophila had a protective effect against α-synuclein-mediated
neurodegeneration, presumably by targeting α-synuclein aggregates
for proteolytic degradation [157–159]. It appears that ubiquitination of
α-synuclein at Lys 6 interferes with its aggregation, but its modiﬁcation
at other residues may be promoting aggregation.
4.3.2. SUMOylation
Small ubiquitin-like modiﬁers (SUMOs) are small proteins that dis-
play signiﬁcant structural similarities to ubiquitin and can also formpro-
tein adducts in a similar fashion.Only one yet unidentiﬁed lysine residue
at the protein N-terminus was shown to be modiﬁed by SUMO1 (Fig. 3,
brown box) [160]. SUMOylation of α-synuclein was shown to promote
its aggregation and decrease its toxicity in COS-7 cells [161].
4.3.3. Modiﬁcation by advanced glycation end-products
Reducing sugars and sugar-derived aldehydes can react with the
amino groups of the proteins to form Schiff base adducts. Rearrangement
of these adducts can lead to the heterogeneous set of adducts known as
advanced glycation end-products (AGEs) [162]. It has been shown that
AGEs andα-synucleinwere similarly distributed in LBs of PD and LBDpa-
tients and that α-synuclein was crosslinked by AGEs [163]. This cross-
linking was shown to promote α-synuclein aggregation and ROS
generation in SH-SY5Y cells [164]. Formation of α-synuclein-AGE ad-
ducts with either D-ribose or methylglyoxal shifted its aggregation path-
way toward oligomer formation [165,166]. These oligomers were
cytotoxic and had a molten globule-like secondary structure [165,166].
4.3.4. Modiﬁcation by lipid-derived aldehydes
Highly reactive aldehydes (for example, 4-hydroxy-2-nonenal and
malondialdehyde) are also produced by lipid peroxidation [167]. Simi-
lar to sugar-derived aldehydes, these lipid-derived aldehydes react
with α-synuclein and promote the formation of stable β-sheet rich cy-
totoxic oligomers [168–170]. Interestingly, oligomers formed afterreactions with 4-hydroxy-2-nonenal and 4-oxo-2-nonenal had differ-
ent structures and morphologies [169].
Overall, lysine modiﬁcation of α-synuclein tends to promote the
formation of oligomers at the expense of ﬁbrils. This is likely due to
the ability of more ﬂexible structures of oligomers to accommodate
these modiﬁcations. Similar behavior has been observed for other
amyloidogenic peptides and proteins [171–173].
4.3.5. Transglutaminase crosslinking
Both inter- and intramolecular crosslinking between lysine and glu-
tamine residues is catalyzed by a tissue transglutaminase [174]. In PD
nigral dopamine neurons, α-synuclein was shown to be heavily cross-
linked in this fashion, and the extent of crosslinking correlated with the
disease progression [175,176]. The exact localization of modiﬁcation
sites in the protein is not known as yet [175]. For the full-length α-
synuclein Gln79, Gln99 and Gln109 were found to serve as crosslink ac-
ceptors and Lys60 was identiﬁed as one of the crosslink donors (see
Fig. 3, red ovals) [177,178]. Intramolecular crosslinking of α-synuclein
with low concentrations of transglutaminase resulted in altered confor-
mational and immunological properties of the protein [177]. In these
Fig. 4. Methionine and tyrosine oxidation scheme. A — Tyr nitration, B — Tyr dimerization, and C — Met oxidation.
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dues at the N-terminal region of the protein. Crosslinks inhibited α-
synuclein ﬁbril formation and promoted oligomer formation [177, 179].
These crosslinked oligomers were primarily unstructured and unable
to disrupt lipid bilayers [179]. α-Synuclein crosslinking in the presence
of lipid bilayers primarily produced a Lys58-Gln99 crosslink [178]. α-
Synuclein crosslinked in this fashion accelerated ﬁbril formation from
the wild-type protein as detected by ThT ﬂuorescence [178]. Overall,
the effects of α-synuclein crosslinking on its aggregation depend on
the position of the crosslink, with most crosslinks promoting the forma-
tion of unstructured, relatively non-toxic oligomers.
4.4. Truncation
N-terminal and C-terminal truncations are common modiﬁcations of
α-synuclein, and α-synuclein fragments are often associated with LBs
[180,181]. C-terminal truncations are the most common modiﬁcations,
with the cleavage site usually located between residues 115 and 135
[182]. The resulting α-synuclein fragments form ﬁbrils more readily
compared to the full-length protein, andwere proposed to initiate its ag-
gregation in vivo and in vitro [66, 180,181, 183]. Detailed studies have
shown that removal of the C-terminal domain that serves as an intramo-
lecular chaperone destabilizes the monomeric state of α-synuclein and
accelerates its aggregation [47, 184]. The increased aggregation propensi-
ty of α-synuclein fragments correlates with their higher toxicity in vivo.
Co-expression of α-synuclein fragments truncated at residues 110 and
120 with wild-type protein in the cell cultures resulted in increased cell
death [180, 185]. Experiments in transgenic animals expressing α-
synuclein fragments also usually showed neuronal loss and lower dopa-
mine levels, especially if wild-type α-synuclein and its fragments were
co-expressed [186–188].
4.5. N-terminal acetylation
Analysis of synuclein forms present in LBs fromDLB patients by two-
dimensional immunoblot analysis andmass spectroscopy revealed that
N-terminal acetylationwas a common posttranslational modiﬁcation of
this protein [182]. N-terminal acetylation of cytosolic proteins iscatalyzed by the N-terminal acetyltransferase B complex (NatB). This
is a rather common modiﬁcation, especially for the proteins in which
the initiatingMet residue is retained [189]. The exact roles of this mod-
iﬁcation for modulation ofα-synuclein structure, function, aggregation,
and cytotoxicity are not known as of yet. However, it is believed that N-
terminal acetylation is required for the proper interactions of α-
synuclein with the membrane [190]. In transgenic yeast, α-synuclein
showed no cytotoxicity when expressed in a strain lackingNatB activity
[190].
4.6. PTMs and intrinsically disordered nature of α-synuclein
Fig. 3C represents the results of disorder prediction for human α-
synuclein by several disorder predictors: PONDR® VL3 [78, 191],
PONDR® VSL2 [192], RONN [193], and IUPred [194]. It can be seen
that α-synuclein is predicted to be almost completely disordered by
all these predictors (as disorder probability scores≥0.5 correspond
to a prediction of disorder), emphasizing that its sequence is typical
of the intrinsically disordered proteins. Therefore, Fig. 3 clearly
shows that all functionally important sites of α-synuclein, as well as
all its PTM sites, are located inside the disordered sequence. This em-
phasizes the importance of the intrinsically disordered nature of this
protein for its function.
5. Modulating α-synuclein aggregation by various environmental
factors and interactions with other proteins and small molecules
5.1. Effect of macromolecular crowding
The environment inside a living cell is extremely crowded. The
concentration of macromolecules, including proteins, nucleic acids,
carbohydrates, and small solutes within a living cell can be as high
as 400 mg/ml [195], with the intracellular solutes taking up about a
half of the total cellular volume [195–198]. The extracellular environ-
ment is crowded as well, with protein concentrations in plasma as
high as 80 mg/ml [198]. Obviously, the volume occupied by solutes
is unavailable to other molecules, a phenomenon known as “excluded
volume effects” [195, 199]. In crowded environments the structures
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[200,201]. Aggregation of intrinsically disordered proteins is signiﬁ-
cantly accelerated by crowding because aggregates and aggregation
intermediates are more compact than unfolded monomers [200,
202–204]. For example, the ﬁbrillation of prion protein and tau
(244–441) fragment was also accelerated by the presence of crowd-
ing agents [205]. However, the effects of crowding on the structure
and aggregation of folded proteins are more complex. For example,
crowding had only small effects on high-afﬁnity protein–protein
complexes [206], while formation of a low-afﬁnity complex between
GFP analogs CyPet and YPet [207] was disrupted, and these proteins
aggregated instead. When aggregation of a model β-hairpin peptide
was studied in the presence of crowding agents, the lag time for ag-
gregation was increased but the aggregation rate was not affected
[208].
In case of α-synuclein, high concentrations of various types of
crowding agents (polyethylene glycols, polysaccharides or other pro-
teins) were shown to accelerate its ﬁbril formation in vitro[209,210].
The effect increased with the increasing length of polymer, as well as
with the increasing polymer concentration. However, the lag time and
the ﬁbril elongation ratewere affected differently by different crowding
agents with the stronger effect observed on the nucleation rate of ﬁbril
formation [211–213]. The formation of α-synuclein protoﬁbrils was
also accelerated by the presence of the crowding agents [210]. The ef-
fects of other aggregation-promoting additives (metal ions, pesticides)
were cumulative with the effects of the crowding agents [211,
213,214]. It seems clear that in the crowded cellular environment, α-
synuclein is even more susceptible to aggregation than in dilute
solution.
5.2. The effect of anions
Anions were shown to induce partial folding of α-synuclein at
neutral pH, forcing the formation of an amyloidogenic partially folded
intermediate and accelerating ﬁbril formation in this protein. The
magnitude of the ﬁbrillation accelerating effect followed the position
of the anion in the Hofmeister series, indicating that the major role of
anions in α-synuclein ﬁbrillation is their modulation of protein–
water interaction, although electrostatic effects have to be taken
into account as well [215]. Therefore, the enhanced ﬁbrillation of α-
synuclein in the presence of anions is the result of the loss of the
uncompensated charge, which is a factor promoting the soluble un-
folded conformation, and an increase in the preferential hydration,
which promotes partial folding and aggregation by strengthening hy-
drophobic interactions. Both nucleation and ﬁbril growth are affected
by a combination of these two effects. The addition of small quantities
of salts eliminates the strong electrostatic repulsion between the res-
idues in the negatively charged C-terminal domain of α-synuclein,
giving rise to its partial folding to the amyloidogenic conformation.
High concentrations of salts act similar to crowding agents to bring
about the dehydration of α-synuclein, further promoting its aggrega-
tion [215].
5.3. Role of environmental toxins: pesticides
Several lines of evidence point to environmental exposure as a po-
tential contributing factor in the pathogenesis of PD [216–222]. Both
epidemiological and clinical observations reveal pesticides and herbi-
cides, especially paraquat and rotenone, as important environmental
PD risk factors [223]. Since rotenone inhibits mitochondrial electron
transfer and paraquat catalyzes ROS formation, both of them induce
oxidative stress. Administration of paraquat or rotenone to mice or
rats led to the overexpression of α-synuclein, presumably to combat
the oxidative stress caused by the pesticides [18, 224–226]. Higher
levels of α-synuclein led to accumulation of α-synuclein-containing
aggregates within the neurons of substantia nigra. In addition, thesepesticides were shown to promote aggregation of α-synuclein in
vitro in a dose-dependent manner [224, 227,228]. It has been pro-
posed that their effect is due to the speciﬁc stabilization of the amy-
loidogenic partially folded conformation of α-synuclein, although
they may also promote oxidative modiﬁcation of the protein.
5.4. Role of environmental factors: metals and α-synuclein aggregation
The possible role of heavy metals in the etiology of PD has been
proposed early on based on the results of epidemiological studies
[229–235] and from the postmortem analysis of the brain tissues of
PD patients [236–238]. For example, the analysis of the PD mortality
rates in Michigan revealed that counties with an industry in the
paper, chemical, iron, or copper related-industrial categories had sig-
niﬁcantly higher PD death rates than counties without these industries
[234]. An epidemiological study conducted in Quebec established that
an increased risk for PD is associated with long-term occupational ex-
posure to manganese, iron, and aluminum [232,233]. A population-
based case–control study in Detroit suggested that chronic occupational
exposure tomanganese or copper, or to dual combinations of lead, iron,
and copper, is associated with increased incidences of PD [229, 235]. In
addition to epidemiological data, postmortem analysis of brain tissues
from patients with PD shows a considerable increase in total iron,
zinc, and aluminum content of the Parkinsonian substantia nigra com-
pared to control tissues [236–239]. Another study revealed that the cen-
tral nervous system tissues of ﬁsh exposed to elevated metal ion
concentrations had increased levels of α-synuclein aggregates [240].
Overall, increased levels of heavy metals in the environment appeared
to correlate with increased incidence of PD.
While metal ions can cause brain damage directly [241–245], the
effect of metals on PD is at least partially due to their effect of the ag-
gregation of α-synuclein. Several possible mechanisms for metal-
stimulated aggregation of α-synuclein can be envisaged. The simplest
would involve direct interactions between α-synuclein and metal
ions leading to structural changes inα-synuclein. In vitro experiments
indeed showed that α-synuclein aggregation is facilitated by the
presence of Cu2+[246], and other metal ions [247]. Redox-active
metal ions may also be able to inﬂuence misfolding of α-synuclein
via its oxidation. Since we discussed the effect of oxidation on α-
synuclein earlier, here we will consider the direct effects of metal
ions on α-synuclein conformation and aggregation.
Fig. 5 shows that at physiological conditions in the presence of milli-
molar concentrations of various metal cations, α-synuclein adopted a
partially folded conformation. This conformation is characterized by an
increased amount of ordered secondary structure (Fig. 5A), changed en-
vironment of tyrosine residues (Fig. 5B), increased protection of these
residues from quenching (Fig. 5C), and by the appearance of solvent-
accessible hydrophobic surfaces as detected by the ﬂuorescent probe
ANS (Fig. 5D) [247]. The ability of a given cation to induce structural
changes in α-synuclein was proportional to the cation's charge density
[247]. It was proposed [247] thatmetal ions stabilize the partially folded
conformation of α-synuclein by decreasing the electrostatic repulsion
between the negative charges in this protein. To some extent this situa-
tion is similar to the anion-induced folding of acid unfolded globular
proteins, when the electrostatic repulsion is reduced by binding of
counter-ions and protein conformation becomes more compact [30,
36, 248–251]. Cations that were the most efﬁcient in promoting partial
folding ofα-synuclein also converted the highest proportion of this pro-
tein to amyloid ﬁbrils, presumably due to a high aggregation propensity
of this partially folded conformation. Amore detailed analysis of effect of
individual metal ions on α-synuclein aggregation is presented below.
5.4.1. Aluminum
Exposure to aluminum was one of the conditions linked to the PD
pathology via the epidemiological studies and the postmortem analy-
sis of the brain tissues of PD patients [232,233, 236–239]. Incubation
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absorbance, intrinsic ﬂuorescence and ANS ﬂuorescence spectra con-
sistent with the formation of the partially folded intermediates de-
scribed above [247, 252]. At low protein concentrations (b35 μM)
these changes occurred simultaneously, were rapid, reversible, and
independent of protein concentration, indicating an intramolecular
conformational change [30]. Al3+-induced partial folding of α-
synuclein was also conﬁrmed using the selective non-covalent adduct
protein probing mass spectrometry (SNAPP-MS), which utilized in-
teractions between 18-crown-6 ether and lysine residues to probe
protein structure in the presence and absence of metal ions [253]. It
has been shown that these interactions were altered dramatically in
the presence of 3 μM Al3+, suggesting that Al3+ binding caused a sig-
niﬁcant change in the conformational dynamics of the monomeric
form of α-synuclein [253].
AlCl3 was also shown to promote α-synuclein aggregation. At high
α-synuclein concentrations, the addition of Al3+ induced the forma-
tion of oligomers detected by light scattering [247]. These oligomers
possessed a signiﬁcant amount of ordered secondary structure and
readily converted to ﬁbrils. The addition of 2.5 mM AlCl3 shortened
the lag-time for α-synuclein ﬁbril formation ~3-fold, and increased
the apparent rate of ﬁbril formation ~1.5-fold [247]. α-Synuclein ﬁ-
brils formed in the presence of Al3+ had an altered morphology
which consisted of twisted ribbons with a periodicity of about
100 nm [254]. In the presence of 20% ethanol, Al3+ promoted α-
synuclein oligomer formation [255].
5.4.2. Calcium
A recent study revealed that α-synuclein regulates the pathways
of Ca2+ entry inside the cells [256]. In another study, a link between
Ca2+ homeostasis, α-synuclein, and cytosolic dopamine was estab-
lished, suggesting that interplay between these three molecules can
be responsible for the selective death of the dopaminergic neurons
in the substantia nigra[257]. Using a microdialysis technique it was
shown that α-synuclein binds Ca2+ with an IC50 in micromolar
range. The Ca2+-binding site was assigned to a C-terminal domain
of this protein [258]. These ﬁndings show the importance of α-
synuclein–Ca2+ interactions in vivo.
Like other metal ions, Ca2+ increased the aggregation rate of α-
synuclein. The addition of Ca2+ directed the aggregation of α-synuclein
to a mixture of annular oligomers (70–90 nm in diameter, 4 nm in
height) and spherical oligomers (10–20 nm in diameter) [259,260].
Each annular particle induced by Ca2+ appeared to be composed of a
ring of several spherical particles. No annular oligomers were found
when α-synuclein lacking the C-terminal 15 amino acids was co-
incubated with Ca2+, indicating that the C-terminal Ca2+-binding do-
main was involved in the formation of annular oligomers. Interestingly,
soluble 30–50 nm-sized annular α-synuclein oligomers were isolated
by a mild detergent treatment from glial cytoplasmic inclusions puriﬁed
fromMSA brain tissue [261], and it has been proposed that the formation
of such aggregated species inside the neurons can be inﬂuencedby the in-
creased intracytoplasmic Ca2+ concentration [262]. This is an indication
that Ca2+-dependent aggregation of α-synuclein may occur in vivo as
well.
In addition, Ca2+ was shown to modulate the interaction of α-
synuclein with the cell membranes. While in the absence of Ca2+ α-
synuclein interacts with lipid membranes via the N-terminal domain,
the addition of Ca2+ promotes additional interaction between the
membrane and the C-terminal domain that may lead to aggregation
of this protein [263].
5.4.3. Copper
In addition to binding to C-terminal region of α-synuclein with
low afﬁnity like other metal ions, Cu+ and Cu2+ ions also bind with
nanomolar afﬁnity at the N-terminus of the protein [264–267]. The
high copper afﬁnity of α-synuclein suggests that most of this proteinis copper-bound in vivo. Copper binding may be integral for a physio-
logical function of α-synuclein since it is believed to be involved in
copper and iron metabolism and possess a copper-dependent ferrire-
ductase enzymatic activity [268].
Signiﬁcant effort has beendevoted to the investigation of Cu2+-bind-
ing by α-synuclein. Initially, the primary Cu2+-binding site was shown
to involve His50 as the anchoring residue and other nitrogen/oxygen
donor atoms in a square planar or distorted tetragonal geometry [264].
The acidic C-terminus of the protein was shown to coordinate a second
Cu2+ equivalent with a 300-fold lower afﬁnity [264]. Several recent
studies [267, 269–273] utilized EPR spectroscopy and site-directed mu-
tagenesis to characterize the Cu2+-binding sites of α-synuclein in more
detail. The conclusion was that the highest afﬁnity Cu2+ binding site is
located at the ﬁrst few N-terminal residues of α-synuclein, and the
Cu2+ binding constant at this site is around 100 nM. Some studies
came to the conclusion that His50 is also involved in Cu2+ binding at
this site; however, other studies disputed that.WhenNMR spectroscopy
was used to identify lower-afﬁnity Cu2+-binding sites, as many as 16
different sites capable of binding Cu2+ were found [274], with most of
the lower-afﬁnity sites located in the acidic C-terminal region.
Using AFM-based single-molecule mechanical unfolding it has been
shown that the presence of Cu2+ signiﬁcantly enhances the relative
abundance of the β-like structure in monomeric α-synuclein [275]. It
has been proposed that upon Cu2+ binding, α-synuclein adopts a
more structured conformation that could promote its aggregation
[247, 267, 274, 276]. Cu2+-synuclein complex is also capable of redox cy-
cling, resulting in the generation of oxygen radicals that lead to oxidative
stress and chemical modiﬁcation of α-synuclein [277,278]. Removal of
Cu2+ ions fromα-synuclein by another Cu2+-binding protein abolished
ROS generation [278].
Cu2+ was shown to be an effective accelerator of α-synuclein aggre-
gation even at physiologically relevant concentrations without altering
the morphology of the resultant ﬁbrillar structures [247, 264]. Studies
using α-synuclein fragments allowed Brown and coworkers to propose
that Cu2+ binding may result in dimerization or oligomerization of α-
synuclein [276]. The appearance of α-synuclein oligomers in the pres-
ence of Cu2+ has been conﬁrmed by ESI-MS [279]. It was also shown
that neurotoxicity of α-synuclein oligomers was increased by the pres-
ence of Cu2+[280]. Cu2+-loaded cytotoxic oligomers of α-synuclein
were isolated and shown to possess a unique stellate morphology by
EM analysis [280].
Overall,α-synucleinwas shown to bind copper ionswith high afﬁnity
and may play a role in copper metabolism in vivo. Copper binding accel-
erates the aggregation of α-synuclein and inﬂuences its pathological
effects.
5.4.4. Iron
The interconnection between iron homeostasis, α-synuclein aggre-
gation, and PD is very strong. As it was already pointed out, numerous
epidemiological studies [229–235] and the postmortem analysis of the
brain tissues [236–238] have linked the heavy metal exposure and
metal accumulation in the brain with the PD pathogenesis. Postmortem
analysis of brain tissues frompatients with PD revealed that the substan-
tia nigra of the PD brain is characterized by a shift in the Fe2+/Fe3+ ratio
in favor of Fe3+ and a signiﬁcant increase in the Fe3+-binding protein,
ferritin. Glutathione content was also shown to be signiﬁcantly lower,
conﬁrming the change in the redox status of the environment [237].
The aggregation of α-synuclein may be contributing to this phenome-
non since α-synuclein has been proposed to act as a ferrireductase
[268], and its aggregation is likely to decrease or abolish this activity.
The evidence for the ferrireductase activity of α-synuclein is the ability
of Cu2+-bound α-synuclein to catalyze reduction of Fe3+ to Fe2+in
vitro and increase in Fe2+ levels in the cells overexpressing α-
synuclein in vivo [268].
As a transitionmetal closely associatedwith ROS formation, iron has
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Fig. 5.Metal ion-induced conformational changes inα-synuclein. A. Far-UV circular dichroism spectra of 35 μMα-synucleinmeasured in the absence or presence of 2 mM of the indicated
metals. B. Comparison of the effect of metal ions on the intrinsicα-synuclein ﬂuorescence. Titration curves measured for Al3+ (squares), Zn2+ (diamonds), Mn2+ (inverse triangles), Fe3+
(circles), Fe2+ (triangles), Cu2+ (hexagons), Co3+ (dotted circles) andCo2+ (dotted squares). C. Stern–Volmerplots forα-synucleinﬂuorescence quenchingby Cu2+ (circles), Fe3+ (inverse
triangles) and Fe2+ (squares). D. ANS ﬂuorescence spectrameasured for free dye (solid line) and in the presence of 7 μMα-synuclein and 10–50 mMof the chloride salts of mono-, di- and
trivalent cations. Modiﬁed from Ref. [30].
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produced ROS via redox cycling [281]. However, iron is able to directly
inﬂuence the aggregation of theα-synuclein aswell [282]. Investigation
of α-synuclein oligomer formation in the presence of iron and alcohols
at the single particle level using single-molecule ﬂuorescence tech-
niques and AFM showed that both alcohols and Fe3+ were effective in-
ducers of α-synuclein oligomerization at micromolar concentrations
[88, 255]. The morphologies of the resulting oligomers were different,
with alcohols inducing small oligomers and ferric ions inducing the for-
mation of larger oligomers. It is worth noting that Fe3+ only caused an
effect onα-synuclein aggregation when added in the presence of inter-
mediate concentrations of ethanol (~5%), suggesting that the effect of
Fe3+ depended on the presence of the intermediate I species. Although
both oligomers could seed ﬁbril formation, only Fe3+-induced oligo-
mers were SDS-resistant and could form ion-permeable pores in a
lipid bilayer that were blocked by the oligomer-speciﬁc A11 antibody
[83, 255]. Recently, the bioluminescent protein-fragment complemen-
tation assay (BPCA) was implemented to directly analyze the formation
of toxic α-synuclein oligomers in the cell culture. The assay conﬁrmed
that Fe3+ promoted α-synuclein oligomer formation in living cells
[283].
The binding of Fe3+ was also shown to alter the morphology of α-
synuclein ﬁbrils. The addition of Fe3+ induced the formation of shorter
and thicker ﬁbrils from both wild type and mutant α-synuclein [266].
These observations provide strong support for an important role of
the ferric iron in the formation of toxic α-synuclein oligomers in vivo
[255, 283]. Iron contributes to aggregation ofα-synuclein by both directbinding to the protein, leading to alteration of the aggregation pathway,
and by production of ROS that oxidize α-synuclein.
5.4.5. Lead
Exposure to lead is known to produce aggresome-like inclusion
bodies in target cells as a toxic response [284]. This process was
shown to be controlled by both metallothionine and α-synuclein.
In fact, Pb2+ exposure produced a rapid increase in α-synuclein ex-
pression in cells stably expressing metallothionine. Expression then
decreased over 48 h as Pb2+-induced aggresome-like inclusion bod-
ies containing both metallothionine and α-synuclein were formed
[284]. In an in vitro study, Pb2+ was one of a few metal ions shown
to overcome the methionine oxidation-induced inhibition of the α-
synuclein ﬁbril formation [144]. It appears that, like other metal
ions, lead promotes aggregation of α-synuclein.
5.4.6. Magnesium
There is signiﬁcant evidence that PD is associated with lower
levels of magnesium in brains. Atomic absorption and atomic emis-
sion spectroscopy revealed lower concentrations of magnesium in
the caudate nucleus in Parkinsonian brains in comparison with the
control [285]. This ﬁnding was conﬁrmed by ICP-MS analysis of PD
and control brains, which revealed that Mg2+ concentration was
lower in cortex, white matter, basal ganglia, and brain stem of PD
brains compared to control brains [286]. Magnesium concentration
in cerebrospinal ﬂuid decreased with the duration and severity of
PD [287]. Epidemiological studies suggest that a low dietary intake
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of low Mg2+ intake over generations in rats showed increased neuro-
degeneration of substantia nigra, a link that has been proposed for in-
creased incidence of PD and ALS in Guam [290]. The reason for
correlation between Mg2+ levels and PD is unclear, and could be
due to either direct effect of Mg2+ on protein aggregation or to indi-
rect effects (e.g. inhibition of calcium signaling or requirement for
magnesium as a nutrient).
The effect of Mg2+ on α-synuclein aggregation is rather complex.
Whenα-synuclein was incubated in the presence of highMg2+ concen-
trations (>10 mM), large aggregates composed of densely packed short
ﬁbrils were rapidly formed [291]. However, at low concentrationsMg2+
inhibited α-synuclein aggregation induced either spontaneously or by
incubation with iron [292]. Mg2+was also able to modulate the interac-
tion between α-synuclein and several herbicides and inhibit the
herbicide-induced aggregation of α-synuclein [293]. In this essence,
Mg2+ was very different from other metals ions, all of which strongly
promoted the herbicide-inducedα-synuclein aggregation. Furthermore,
Mg2+ counteracted the effect of othermetal ionswhen theywere present
together [293]. In line with these observations, it was shown that milli-
molar concentrations of Mg2+ protect dopaminergic neurons in the
substantia nigra from MPP+-mediated degeneration in transgenic rats
[294]. These observations suggest that the interaction of Mg2+ with
α-synuclein might play a neuroprotective role by inhibiting the aggre-
gation of the latter.
5.4.7. Manganese
Chronic manganese intoxication, manganism, produces an irrevers-
ible syndrome which bears a striking resemblance to PD, including
ﬁxed gaze, bradykinesia, postural difﬁculties, rigidity, and tremor [295].
Parkinsonism due to chronic manganese intoxication can be separated
from PD by the presence of dystonia and mental status changes [296].
LBs have never the been observed in manganese-induced parkinsonism,
and themajor effects ofmanganese toxicitywere found in the cells of the
striatum and globus pallidus which are not dopaminergic [297].
Althoughmanganism is clearly different from PD, there is a possible
link between chronic exposure toMn2+ and PD [298,299]. For example,
a recent study by Lindquist and coworkers found that PD-related pro-
tein PARK9 is aMn2+ transporter that helps protect the cells fromman-
ganese toxicity [300]. Knockdown of this protein increases α-synuclein
misfolding and toxicity, suggesting the possible involvement of Mn2+.
Mn3+ is able to oxidize α-synuclein resulting in the immediate forma-
tion of di-tyrosine cross-links [247]. Since di-tyrosines can be formed
both intra- and intermolecularly, this modiﬁcation represents an addi-
tional structure- and aggregation-promoting factor.
In fact, co-incubation of α-synuclein with Mn2+in vitro induced a
partial folding of the protein and its ﬁbrillation [247]. Curiously, when
SK-N-MC neuroblastoma cells stably expressing the human dopamine
transporter were transfected with human α-synuclein and exposed to
30–300 μM MnCl2, the viability of cells overexpressing α-synuclein
after 72 h of exposure to Mn2+ was dramatically reduced, suggesting
that Mn2+ may cooperate with α-synuclein in triggering neuronal cell
death such as seen in manganese parkinsonism [301]. A similar effect
has been observed in rat mesencephalic cells [302]. This data indicates
a possible connection betweenMn2+ andα-synuclein in vivo, although
it's not clear whether it's due to direct interaction between them.
5.4.8. Zinc
Zinc has been studied as one of potential environmental factors
exposure to which might favor PD, but no correlation between occu-
pational exposure to zinc and PD progression has been found [230,
234–235, 303]. A recent epidemiological study showed a positive cor-
relation between higher levels of zinc and a decreased risk of PD
[289]. However, the analysis of the Parkinsonian substantia nigra
revealed the enhanced level of zinc in comparison with the control
tissues [237–239]. Zinc was shown to be an effective promoter of α-synuclein aggregation and speciﬁcally its ﬁbrillation in vitro [247,
304]. When the ﬁbrillation of the oxidized form of wild type α-
synuclein and its Met-minus mutants were studied, the presence of
Zn2+ was shown to induce a dramatic acceleration of ﬁbril formation
for all of the oxidized proteins studied in a mutation-dependent man-
ner [142]. The rates of ﬁbrillation for the oxidized α-synucleins in the
presence of Zn2+ could be arranged in the following order: M5L/
M116L/M127L>M116L/M127L>M5L≈M116L≈M127L [142]. This
suggested that methionine sulfoxides of the oxidized α-synuclein
are not directly involved in the coordination of Zn2+ as double and
triple Met→Leu mutants aggregated faster than WT or single mu-
tants. Interaction with Zn2+ decreased the propensity of the Leu-
substituted α-synucleins to oligomerize, indicating that the presence
of Zn2+ caused partitioning in favor of the ﬁbrillation pathway [142].
Zinc was also one of the several metals shown to dramatically accel-
erate the herbicide-induced ﬁbrillation of α-synuclein [293]. Overall,
zinc promotes ﬁbrillation of α-synuclein at the expense of its oligo-
merization in vitro. Its effect in vivo is unclear, and may in fact be
protective.
5.4.9. Interaction of α-synuclein with metal ions: general considerations
In general, there are at least two major types of interactions of the α-
synuclein with metal ions: low-afﬁnity and high-afﬁnity binding. The
low-afﬁnity binding (in themillimolar range) is driven by the electrostat-
ic interactions of themetal ionswith the negatively charged side chains of
α-synuclein and is mostly directed to C-terminal domain of the protein.
Many metals can interact with α-synuclein non-speciﬁcally, resulting in
the effective neutralization of the Coulombic charge-charge repulsion
and stimulating the partial folding of α-synuclein. The resulting partially
folded conformation of α-synuclein is more aggregation-prone [247].
The C-terminus of α-synuclein also contains a speciﬁc, albeit also low-
afﬁnity, metal binding site 119DPDNEA124. Metal binding at this sequence
may be driven not only by electrostatic interactions but also by the resid-
ual structure of the α-synuclein C-terminus [305]. The higher-afﬁnity
metal-binding site has been assigned to several N-terminal residues and
a slightly lower-afﬁnity site is ascribed to the imidazole ring of the sole
histidine residue [306].
There is a signiﬁcant correlation between the propensity of a
metal ion to induce partial folding of the non-oxidized α-synuclein
and its ability to promote ﬁbrillation of this protein [247]. Among
the most effective stimulators of protein partial folding and subse-
quent ﬁbrillation were Cu2+ and Fe2+, which were shown to interact
with α-synuclein speciﬁcally, together with non-speciﬁcally interact-
ing Al3+, Co3+, and Mn2+ [247]. Since there are several different
modes of metal ion interactions with α-synuclein, it is not surprising
that metal binding induces a wide range of conformational changes in
this natively unfolded protein. Metal-induced structural changes vary
from a relatively minor gain of residual ordered structure in the pres-
ence of some monovalent metals to a relatively more pronounced
transformation into the pre-molten globule-like conformation, pro-
moted by interaction with polyvalent ions [247]. Different partially
folded monomeric species can assemble into morphologically and
structurally different oligomers and ﬁbrils. Illustrative examples of
this variability of the metal-stabilized oligomeric forms that include
0.8–4 nm spherical particles induced by Cu2+, Fe3+, and Ni2+; larger
5–8 nm spherical oligomers induced by Mg2+, Cd2+ and Zn2+; and
70–90 nm annular oligomers stabilized by Ca2+ [259]. The morphol-
ogy of the amyloid ﬁbrils and the prevalence of ﬁbrillation vs. oligo-
merization pathways were shown to be strongly dependent on the
nature of the metal ion as well. Such metal-dependent structural var-
iability of monomeric and oligomeric species, together with the
metal-speciﬁc ﬁbril morphology, should be taken into account in
the analysis of the molecular mechanisms of neurodegeneration. De-
tailed structural characterization of α-synuclein–metal complexes
will shed more light on the molecular mechanisms of synucleinopa-
thies. A better connection between the extensive in vitro data on the
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cellular processes triggered by the exposure to heavy atoms should be
established (Fig. 6).
6. Interactions of α-synuclein with other proteins
Several dozen proteins are known to physically interact with α-
synuclein [21, 307–310]. Fig. 3B represents the localization of binding
sites for some known α-synuclein interaction partners. It is of great in-
terest to note that all these interactions are potentially affected either by
familial point mutations inα-synuclein or by one or several of its PTMs,
or by both (cf. Fig. 3A and B). A recent proteomic analysis using a SILAC
technique (stable isotope labeling by amino acids in cell culture) identi-
ﬁed 587 proteins involved in the formation of complexes with α-
synuclein in the dopaminergic MES cells, with 141 proteins displaying
signiﬁcant changes in their relative abundance (increase or decrease)
after theMES cell were treated with rotenone [311]. The list of the indi-
vidually identiﬁed proteins involved in the interactionwithα-synuclein
includes, but is not limited, to PLD2 [312], UCH-L1 [313], parkin [314],
synphilin [315–317], 14-3-3 protein [109, 318], prolyl-isomerase, Pin1
[319], αB-crystallin [320], different PKC isozymes, BAD, ERK [318, 321],
Rab5A [322], ELK-1/ERK-2 complex [323], ERK-1/2, p38MAPK, and
SAPK/JNK mitogen activated kinases (MAPKs) [324], Aβ, [325–327],
MAP1B [328], heterodimeric tubulin [28, 329], tau protein [330,331],
TBP-1 [332,333], phospholipase D [334], protein phosphatase 2A [335],
DAT [336], mitochondrial complex IV enzyme cytochrome oxidase
[337], TH [338], aromatic amino acid decarboxylase [339], DJ-1
[340,341], histones [342], and calmodulin [343,344].
Some of these proteins were shown to stimulateα-synuclein aggre-
gation in vitro at substoichiometric concentrations. The list of these ag-
gregation promoters includes tau [345], histones [345], tubulin [329,
346], and agrin [181]. Except for histones, these proteins have all been
identiﬁed as components of LBs and/or GCIs [181, 307–309, 329, 345].
Since these proteins are aggregation-prone in physiological conditions,
it is likely that they accelerate the aggregation of α-synuclein by cross-
seeding. Cross-seeding of ﬁbril and oligomer formation by the proteins
with different sequences is a well-known process both in vitro and in
vivo. For example, protein A amyloidosis is accelerated by ﬁbrils formed
by several proteins with unrelated sequences [181, 307, 309, 329, 345].
Cross-seeding of α-synuclein aggregation by PrPSc and Aβ ﬁbrils has
been demonstrated both in vitro and in transgenic mouse models
[347,348]. α-Synuclein ﬁbrils were also shown to seed the formation
of tau aggregates in the cell culture [347]. Cross-seeding has been dem-
onstrated for oligomers of amyloidogenic proteins as well. Kayed and
coworkers have shown that both Aβ and α-synuclein oligomers are
able to seed formation of cytotoxic tau oligomers [349]. Thus it is
quite likely that cross-seeding is also the underlying mechanism for
promotion of α-synuclein aggregation by amyloidogenic proteins.
Non-amyloidogenic proteins inﬂuence α-synuclein aggregation
by other mechanisms. For example, the addition of a peptidyl-prolyl
isomerase (PPIase) FKBP accelerated α-synuclein aggregation in
vitro and resulted in the formation of aggregates with clear ﬁbrillar
morphology, while the addition of a PPIase inhibitor suppressed α-
synuclein aggregation [350,351]. Proline isomerization is known to
be a slow step in protein folding, and PPIase addition is known to ac-
celerate aggregation of other proteins such as β-2-microglobulin
[352,353].
6.1. Chaperons
Chaperons provide the cells with potent means to neutralize and
scavenge toxic misfolded proteins. Heat shock proteins (Hsp) are a
family of chaperones that are both constitutively expressed and in-
duced by different stresses that suppress protein aggregation, and
participate in protein refolding and/or degradation. Torsin A, a pro-
tein with homology to yeast Hsp104, co-localizes with α-synucleinin LBs and is found in many peripheral tissues and brain regions
[354–356]. Other heat shock proteins have also been shown to co-
localize with α-synuclein in LBs [357]. The over-expression of torsin A
or other heat shock proteinswas shown to suppressα-synuclein aggre-
gation in the cellular models [357–359]. Yeast Hsp104 inhibited ﬁbrilli-
zation of α-synuclein and its PD-linked mutants in vitro[360].
Moreover, Hsp104was capable of ATP-driven disassembly of oligomers
and ﬁbers composed of α-synuclein and its mutants. Disassembly was
enhanced by the mammalian Hsp70 chaperone system. Co-expression
of Hsp104 and α-synuclein A30P in transgenic rats reduced the forma-
tion of α-synuclein inclusions and prevented neurodegeneration [360].
Inhibition of Hsp90 leading to upregulation of Hsp70 resulted in inhibi-
tion of α-synuclein aggregation in the cell culture models and in vivo
[361].
Using immunohistochemistry and confocal microscopy, it has
been demonstrated that αB-crystallin, a small chaperone that binds
to unfolded proteins and inhibits aggregation, is a prominent compo-
nent of GCIs and LBs [362]. In cultured proteasome-inhibited C6 glio-
ma cells, transfection with GFP-tagged α-synuclein resulted in
ubiquitin- and αB-crystallin-positive aggregates, resembling GCIs in
MSA brains [362]. These studies are supported by the detailed in
vitro analysis, which revealed that αB-crystallin serves as a potent in-
hibitor of wild-type, A30P, and A53T α-synuclein ﬁbrillation [320].
Overexpression of the chaperone Hsp70 prevented dopaminergic
neuronal loss associated with α-synuclein in Drosophila and interfer-
ence with its activity accelerated α-synuclein toxicity [113]. Overex-
pression of Hsp70 also prevented the formation of α-synuclein
aggregates in transgenic mice and its ﬁbrillation in vitro[363,364]
Hsp70 inhibited α-synuclein aggregation by binding to the hydro-
phobic core of the protein and stabilizing its non-toxic disordered
oligomers [365]. However, annular oligomers of α-synuclein were re-
sistant to unfolding by chaperons and inhibited the Hsp70/Hsp40 sys-
tem [366]. In addition, LBs in human postmortem tissue were shown
to immunostain for Hsp70 and Hsp40. Similar results have been ob-
served for inclusions in the brain tissues from patients with DLB,
LBVAD, and NBIAI [113]. These data show that chaperons play an im-
portant role in the neuronal arsenal that mitigates α-synuclein toxic-
ity [113].
6.2. β- and γ-synucleins
Conformational analysis revealed that α-, β-, and γ-synucleins are
natively unfolded under physiological conditions in vitro, and are able
to adopt comparable partially folded conformations at acidic pH or at
high temperatures [367]. Although both α- and γ-synucleins were
shown to form ﬁbrils, β-synuclein did not ﬁbrillate when incubated
under the same conditions [367]. Curiously, the addition of either β-
or γ-synuclein in a 1:1 molar ratio to α-synuclein solution substan-
tially increased the duration of the lag-time and dramatically reduced
the elongation rate of α-synuclein ﬁbrillation [367]. Fibrillation was
completely inhibited at a 4:1 molar excess of β- or γ-synuclein over
α-synuclein [367]. β-Synuclein inhibited α-synuclein aggregation in
animal models as well [368]. The formation of stable mixed tetramers
with α-synuclein has been proposed as a mechanism of inhibition
[369]. This suggests that β- and γ-synucleins may act as regulators
of α-synuclein ﬁbrillation in vivo, potentially acting as chaperones.
As a result, one possible factor in the etiology of PD would be a de-
crease in the levels of β- or γ-synucleins [367].
7. Inhibition of α-synuclein aggregation by small molecules
7.1. Small molecules can alter IDP aggregation pathways
Many small molecules inhibit the aggregation of proteins or alter
their aggregation pathway. The mechanisms of actions of these com-
pounds usually involve non-covalent or covalent binding to the
Potentially neurotoxic
Potentially neuroprotective
Fig. 6. Different aggregated forms achievable by the partially folded α-synuclein either under the different experimental conditions or during the ﬁbrillation/aggregation process.
Partially folded species together with soluble oligomeric forms (doughnuts and spheroids) are potentially neurotoxic, whereas insoluble aggregated forms (amorphous aggregates
and ﬁbrils) are potentially neuroprotective.
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aggregates. Usual structure-based drug development approaches are
not applicable to IDPs due to their high conformational plasticity.
One of the successful approaches has been to use small molecule
binding to alter the conformation of IDP aggregates. Since toxicity
and biological activity of both oligomers [82, 370,371] and ﬁbrils
[372]vary signiﬁcantly with their structure, small molecules may be
able to direct protein aggregation to non-toxic aggregates. There are
many examples of this approach in literature. For example, Necula
and coworkers [373,374] have shown that many known inhibitors
of protein aggregation act by altering the aggregation pathway favor-
ing the formation of either amyloid ﬁbrils or a speciﬁc type of amyloid
oligomers. This has been also shown for many individual small mole-
cules such as methylene blue [373,374], polyphenols [371, 375–377],
and many others.
7.2. Effects of small molecules on α-synuclein aggregation pathway
Several compounds have been shown to interfere with aggregation
of α-synuclein. For example, rifampicin eliminated α-synuclein ﬁbrilla-
tion in vitro. It was also able to disaggregate preformed α-synuclein ﬁ-
brils in a concentration-dependent manner, and led to the formation
of soluble oligomers composed of partially folded α-synuclein [378].
Theﬂavonoid baicalein is themain component of the traditional Chinese
herbal medicine Scutellaria baicalensis[379–383]. Micromolar concen-
trations of baicalein, or its oxidized forms, were shown to inhibit the for-
mation of α-synuclein ﬁbrils and disaggregate preformed ﬁbrils, giving
rise to non-toxic soluble oligomers both in vitro and in vivo[384,385].
Structural analysis of baicalein-stabilized oligomers revealed that their
packing density is intermediate between that of pre-molten globules
and typical globular proteins (according to the Kratky plot analysis ofthe SAXS data), and their secondary structure is relatively well-
developed (according to the FTIR and CD analysis) [386]. These oligo-
mers were characterized by high thermodynamic stability and were
able to inhibit ﬁbrillation of non-baicalein-treated α-synuclein. Similar
oligomers or large amorphous aggregates were formed when α-
synuclein or its ﬁbrils were incubated with EGCG [387], curcumin
[388–390], other polyphenols [391], an anti-PD drug selengiline [392]
and many other compounds [393–395]. These compounds were also
shown to alleviate the cytotoxicity of α-synuclein aggregates in vivo or
in cell cultures. In addition, compounds found in cigarette smoke such
as nicotine and hydroquinone had the same effect [396]. This data may
be relevant to the results of epidemiological studies, showing that smok-
ing and PD incidence are negatively correlated.
In general, we can see that inhibition of α-synuclein aggregation
by small molecules usually occurs by redirection of the aggregation
pathway of this protein toward large, non-toxic oligomeric aggre-
gates. In addition to this approach, the drugs could be targeted direct-
ly to disordered α-synuclein monomer where their binding would
promote structure formation and stabilize the monomeric state.
While chemical chaperons that function in this fashion (for example,
4-phenyl butyrate) have been shown to alleviate toxicity of α-
synuclein aggregates [397,398], it has not been shown that they do
so by stabilizing the monomeric state of the protein. However, this
method has been successfully applied to transcription factors and
we will brieﬂy discuss some examples below.
7.3. Stabilization of IDP monomers by small molecules
The c-Myc transcription factor is an attractive drug target since it
is overexpressed in most human cancers and, under normal condi-
tions, regulates large numbers of genes important in key cellular
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[399]. In order to be active, c-Myc has to heterodimerize with its part-
ner, Max. The unbound forms of both Max and c-Myc are disordered
and undergo mutual coupled binding and folding when their leucine
zipper domains interact to form a helical coiled-coil [400,401]. One
approach to c-Myc inhibition has been to disrupt the formation of this
dimeric complex. In a search for effective inhibitors of the c-Myc–Max
interactions, high throughput screening led to the discovery of several
speciﬁc inhibitors [402,403]. These molecules were shown to bind to
oneof three discrete siteswithin theMax-binding domain of c-Myc, dis-
sociate c-Myc–max dimers, and stabilize unfolded c-Myc monomers.
EWS-FLI1 acts as a transcription factor modulating a diverse group
of target genes [404,405]. The C-terminal disordered region of EWS-
FLI1 has been proposed to be responsible for the critical interaction of
this TF with other transcriptional regulators [406]. A screen of a library
of 3000 compounds revealed a small molecule that was able to bind to
EWS-FLI1 and thereby to inhibit interaction of this protein with RNA
helicase A [407], suggesting that the lead compound binds at an intrin-
sically disordered protein–protein interaction site.
These results show that it is indeed possible for small molecules to
stabilize IDP in a monomeric form. While this approach has not yet
been applied to aggregation-prone IDPs like α-synuclein, it may be
successful for them as well.
8. Interaction of α-synuclein with membranes
α-Synuclein contains several class A2 lipid-binding helices, distin-
guished by clustered basic residues at the polar–apolar interface, po-
sitioned ±100° from the center of apolar face; a predominance of
lysines relative to arginines among these basic residues; and several
glutamate residues at the polar surface [408–410]. These structural
features allow α-synuclein to bind to synthetic vesicles containing
acidic phospholipids and to cellular membranes [410,411]. In presyn-
aptic termini, monomeric α-synuclein exists in equilibrium between
free and membrane- or vesicle-bound states [412]. The equilibrium
is tightly regulated, and it has been estimated that approximately
15% of α-synuclein is membrane-bound within the synaptic termini
[413].
The binding of α-synuclein to the membranes was shown to be ac-
companied by a dramatic increase in α-helix content [410,411]. α-
Synuclein forms a variety of helical structures upon membrane binding,
depending on the composition of the membrane. The binding of α-
synuclein to SDSmicelles led to the formation of two anti-parallel curved
α-helices (Val3-Val37 and Lys45-Thr92) connected by a well-ordered,
extended linker, whereas the acidic C-terminal region (Asp98-Ala140)
remained unstructured [56]. Sarkosyl micelles promoted a similar struc-
ture of the protein, except the linker between two helices was unstruc-
tured [48]. However, binding to a lipid bilayer caused α-synuclein to
primarily form a single curved α-helix encompassing residues 1–90
[414,415].
Using 2H- and 31P-NMR spectroscopy it has been shown that the as-
sociation of α-synuclein with negatively charged membranes of multi-
lamellar vesicles (MLVs) has a profound effect upon the integrity of
bilayers containing anionic phospholipids, prompting the formation of
nonbilayer or small vesicular structures [416]. EPR and ﬂuorescence
spectroscopy analysis revealed that the lipid packing in SUVs is also af-
fected by interaction with α-synuclein [417]. In fact, it has been
shown that protein binding led to increasing chain melting tempera-
tures and to enhanced cooperativity of the phase transitions, which
was attributed to defect healing in the curved vesicle membranes
[417]. The binding of α-synuclein to the membranes also increased
themembrane curvature and converted the large phospholipid vesicles
into tubules and small vesicles [418,419]. Tubule formation was espe-
cially favored for membranes with low anionic lipid content [419]. It
has also been found that monomeric α-synuclein bound to the lipid
membrane can efﬁciently prevent lipid oxidation. The antioxidantfunction ofα-synuclein was attributed to its facile oxidation via the for-
mation ofmethionine sulfoxide (see above). These ﬁndings suggest that
the inhibition of lipid oxidation by α-synuclein may be a physiological
function of the protein [420].
The interaction ofα-synucleinwith themembranes alters the kinetics
and pathways of its aggregation in vitro. The effects ofmembrane binding
varied from inhibition to acceleration of α-synuclein aggregation
[421–428]. Membrane-induced formation of both β-sheet rich [425,
429] and α-helical oligomers [430,431] has been observed. A detailed
study of α-synuclein aggregation in the presence of phospholipid mem-
branes found that the structures and heterogeneity of the aggregates
strongly depended on the experimental conditions [432].
9. PD-associated mutants of α-synuclein
Finding that a small fraction of PD patients have a familial form of
parkinsonism with an autosomal-dominant pattern of inheritance
raised considerable interest in understanding the role of genetic fac-
tors in the etiology of PD [433]. Several families have been identiﬁed
whose incidence of PD is signiﬁcantly greater than in age-matched
controls [434,435]. Analysis of point mutations present in these fam-
ilies showed three mutations in α-synuclein gene: A53T, A30P, and
E46K [3, 5,6]. In families with the A53T mutation, 85% of patients
who expressed the mutant gene had clinical features of PD [3]. Fur-
thermore, the triplication of the wild-type gene has been reported
in a large family from Iowa [7–9]. Mutations in α-synuclein were
shown to produce a fulminant disease that includes Parkinsonism,
but is much more widespread and may resemble DLB [107]. Further-
more, the disorder was shown to also be more progressive, tending to
have an earlier onset than sporadic PD [107]. These ﬁndings strongly
indicate that a single mutation in the human α-synuclein gene is suf-
ﬁcient to account for the PD phenotype.
Detailed analysis using a combination of low resolution techniques,
such as CD, FTIR, ﬂuorescence, and several hydrodynamic approaches
[87, 100–103, 379, 436–439] revealed that the PD-related point muta-
tions A30P, E46K, and A53T do not affect the global structure of
humanα-synuclein monomer [100,101, 439]. However, NMR spectros-
copy revealed that the A30P mutation strongly attenuated the helical
propensity found in the N-terminal region of wild type α-synuclein
[52]. The A53T mutation was found to exert a more modest inﬂuence
on local structural propensity, resulting in a slightly enhanced prefer-
ence for extended conformations in a small region around the site of
mutation [52]. The E46Kmutation resulted in subtle changes in the con-
formation of the monomeric protein [440] and enhanced the contacts
between N- and C-termini of the protein [441]. These mutations were
also proposed to modify long-range transient structure in α-synuclein
[47], although this conclusion remains controversial [442]. All three
PD-related point mutations were shown to accelerate α-synuclein ag-
gregation in vitro[87, 100–103, 437–439, 443]. A30Pmutation promoted
α-synuclein oligomer formation, while A53T and E46K mutations pro-
moted ﬁbrillation. Overall, it is clear that all three PD-related mutations
ofα-synuclein alter its secondary structure and promote its aggregation.
10. Conclusions
The molecular basis of PD (and other synucleinopathies) appears
to be tightly coupled to the aggregation of α-synuclein. The focus of
studies on the molecular mechanisms of PD pathology became
strongly α-synuclein-centric due to the two important discoveries
made in 1997, the demonstration that a speciﬁc mutation in the α-
synuclein gene is related to familial cases of early-onset PD [3], and
the demonstration that α-synuclein is highly abundant in LBs [4].
Much has been learned about α-synuclein structure, function, and ag-
gregation properties after these discoveries.
Accumulated data show that α-synuclein is an intrinsically disor-
dered protein that can adopt a number of different conformational
277L. Breydo et al. / Biochimica et Biophysica Acta 1822 (2012) 261–285and aggregation states depending on the conditions and cofactors.
The intrinsically disordered nature of α-synuclein, its chameleon be-
havior, and conformational plasticity, together with the breadth of
functions and the wide spectrum of interactions ascribed to this pro-
tein, are believed to be central to its pathogenicity. In a model depict-
ing α-synuclein aggregation, this protein prior to aggregation exists
as a mixture of the natively unfolded (non-sticky) form and a set of
partially folded conformations (many of which are sticky). Under
normal, non-pathological conditions, this equilibrium is essentially
shifted toward the non-sticky unfolded conformation. However, the
equilibrium is extremely unstable and can easily be shifted toward
the amyloidogenic conformation(s) by subtle changes in the protein
environment. This partial folding might lead to α-synuclein self-
association, which is facilitated by the formation of solvent-exposed
hydrophobic clusters on the surface of a partially folded protein.
Among the factors known to shift conformational equilibrium and
promote α-synuclein oligomerization and aggregation in vitro are: an
introduction of PD-related mutations; an increase in concentration; a
decrease in pH; an increase in temperature; an addition of amphi-
pathic molecules (e. g. various agrochemicals, such as herbicides or
pesticides); an addition of metal ions and other small charged mole-
cules; interaction with charged biopolymers; interaction with other
proteins; interaction with membrane; and immersion of a protein
into a crowded environment. Different factors may stabilize different
partially folded conformations and therefore produce different aggre-
gation states of α-synuclein, such as various soluble oligomers, amor-
phous aggregates, or amyloid-like ﬁbrils.
There are three major molecular mechanisms proposed to explain
the neurotoxicity of α-synuclein and its aggregates — the mechanical
distortion of cellular compartments/processes, toxic gain of function,
and toxic loss of function. Any of the aggregated species could potential-
ly be neurotoxic. However, the largest cytotoxicity is believed to be
expressed by soluble oligomers. The important notion is that although
PD and other synucleinopathies are characterized by the accumulation
of α-synuclein-containing deposits, these neurodegenerative maladies
are multifactorial diseases whose pathogeneses cannot be, and should
not be, explained solely by α-synuclein aggregation, and various other
factors have to be taken into account. In fact, the pathogenesis of synu-
cleinopathies is very complex in nature, and these maladies are known
to be initiated by numerous factors, including genetic predisposition,
toxic insults, failure of the chaperone system, proteasomal misfunction,
rare early-onset cases of the autosomal origin, oxidative damage, etc.
[99].
This multifactorial nature of PD and other synucleinopathies, and a
limited understanding of the key molecular events provoking neuro-
degeneration, are among the major reasons determining the lack of
drugs for the successful inhibition and cure of these diseases [444].
Another factor is the lack of the precise knowledge of the nature of
the neurotoxic species that accumulate during α-synuclein misfold-
ing and aggregation, and eventually lead to cell death. As a result,
the current arsenal of anti-Parkinsonian drugs is not able to halt or re-
tard neuron degeneration, and all drugs developed so far treat disease
symptoms.
However, even though synucleinopathies are multifactorial disor-
ders, the detailed analysis of the α-synuclein function, misfunction,
and aggregation could provide an important basis for the future de-
velopment of some effective therapeutic protocols. In fact, since
many of the disease-promoting factors are directly or indirectly relat-
ed to α-synuclein misfolding or abnormal processing, functioning, or
aggregation, the identiﬁcation of small molecules that would be able
to inhibit α-synuclein deposition or reverse ﬁbril/oligomer formation
may represent a critical ﬁrst step toward a better understanding of
the pathophysiology of proteinaceous inclusion formation in this set
of human diseases.
Obviously, great caution should be taken in developing and exam-
ining drugs that inhibit α-synuclein ﬁbrillation or promote thedisaggregation of preformed ﬁbrils. In fact, since some small α-
synuclein oligomers are extremely neurotoxic, halting the ﬁbrillation
process at early stages can promote the formation of such small toxic
oligomers, and can therefore do more harm than good. Similarly, en-
hanced neurodegeneration can be promoted by small molecules that
are able to disaggregate ﬁbrils to smaller oligomers or soluble
aggregates.
There are several potential solutions for these problems. One of
them is a search for small molecules stabilizing the intrinsically disor-
dered conformation of α-synuclein or completely blocking its aggre-
gation, or resulting in the complete disaggregation of the preformed
aggregates down to the monomeric state. Alternatively, one can
search for chemical compounds that can either clear toxic misfolded
proteins or protect neurons from their impact. Finally, a very promis-
ing approach relies on compounds that promote protein aggregation,
accelerate formation of large inclusions, and eliminate the toxic ef-
fects of misfolded protein conformations and small oligomers
[394,395]. This approach is based on the observation that large pro-
teinaceous inclusions might play a neuroprotective role, and there-
fore the stimulation of fast formation of large protein aggregates
could be used as a therapeutic means for the affected neurons [395].
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